Some generics makers are responding to industrywide pricing pressure by bulking up via M&A. Not Novartis.
China issued expansive drug policy change guidelines, the FDA rejected Mylan and Biocon's Neulasta biosim, C-Bridge hired ex-GSK exec Hussain.
Indian CDMO Piramal Pharma Solutions is beefing up its global API production, including in the U.S., where it has expanded in recent years.
The FDA has issued Biocon and partner Mylan a complete response letter for their biosimilar of chemotherapy drug Neulasta tied to manufacturing.
South Korean drugmaker gets a U.S. regulatory warning, new results in Takeda and Myovant’s trial for relugolix to treat uterine fibroids and more.
AbbVie began the next phase of its Singapore manufacturing expansion with a new biologics unit that complements the plant's existing API production.
Dasan E&T was handed an FDA warning letter based on an inspection earlier this year that found numerous testing and manufacturing issues at its plant.
GlaxoSmithKline has worked hard to put 2013’s China bribery scandal behind it. And a U.S. judge just gave it an assist in that department.
While other companies fret about the impact of Brexit, Japan's Takeda will make another investment in its production operations in the European Union.
Amgen inked a biosim deal with Simcere, Gilead won a Chinese nod for Sovaldi, and Shanghai Pharma is in talks to buy part of Alvogen.